183 related articles for article (PubMed ID: 10781859)
1. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).
Matsuo K; Yoshikawa T; Asanuma H; Iwasaki T; Hagiwara Y; Chen Z; Kadowaki SE; Tsujimoto H; Kurata T; Tamura SI
Vaccine; 2000 Jun; 18(24):2713-22. PubMed ID: 10781859
[TBL] [Abstract][Full Text] [Related]
2. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
[TBL] [Abstract][Full Text] [Related]
3. Cytokine mRNAs in the nasal-associated lymphoid tissue during influenza virus infection and nasal vaccination.
Matsuo K; Iwasaki T; Asanuma H; Yoshikawa T; Chen Z; Tsujimoto H; Kurata T; Tamura SS
Vaccine; 2000 Jan; 18(14):1344-50. PubMed ID: 10618531
[TBL] [Abstract][Full Text] [Related]
4. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.
Asanuma H; Hirokawa K; Uchiyama M; Suzuki Y; Aizawa C; Kurata T; Sata T; Tamura S
Vaccine; 2001 Jul; 19(28-29):3981-9. PubMed ID: 11427274
[TBL] [Abstract][Full Text] [Related]
5. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
[TBL] [Abstract][Full Text] [Related]
6. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
7. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine.
Tamura SI; Samegai Y; Kurata H; Kikuta K; Nagamine T; Aizawa C; Kurata T
Vaccine; 1989 Jun; 7(3):257-62. PubMed ID: 2781859
[TBL] [Abstract][Full Text] [Related]
9. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB.
Tamura S; Funato H; Nagamine T; Aizawa C; Kurata T
Vaccine; 1989 Dec; 7(6):503-5. PubMed ID: 2609726
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination.
Hirabayashi Y; Kurata H; Funato H; Nagamine T; Aizawa C; Tamura S; Shimada K; Kurata T
Vaccine; 1990 Jun; 8(3):243-8. PubMed ID: 2363302
[TBL] [Abstract][Full Text] [Related]
13. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
Okamoto S; Matsuoka S; Takenaka N; Haredy AM; Tanimoto T; Gomi Y; Ishikawa T; Akagi T; Akashi M; Okuno Y; Mori Y; Yamanishi K
Clin Vaccine Immunol; 2012 Jul; 19(7):979-90. PubMed ID: 22552600
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit.
Gizurarson S; Tamura S; Aizawa C; Kurata T
Vaccine; 1992; 10(2):101-6. PubMed ID: 1539462
[TBL] [Abstract][Full Text] [Related]
16. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit.
Tamura S; Kurata H; Funato H; Nagamine T; Aizawa C; Kurata T
Vaccine; 1989 Aug; 7(4):314-20. PubMed ID: 2815967
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments.
Tamura S; Hasegawa H; Kurata T
Jpn J Infect Dis; 2010 Jan; 63(1):8-15. PubMed ID: 20093755
[TBL] [Abstract][Full Text] [Related]
18. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit.
Kikuta K; Hirabayashi Y; Nagamine T; Aizawa C; Ueno Y; Oya A; Kurata T; Tamura S
Vaccine; 1990 Dec; 8(6):595-9. PubMed ID: 1965078
[TBL] [Abstract][Full Text] [Related]
19. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
20. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.
Hagiwara Y; Komase K; Chen Z; Matsuo K; Suzuki Y; Aizawa C; Kurata T; Tamura S
Vaccine; 1999 Jul; 17(22):2918-26. PubMed ID: 10438064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
